Regeneron reports positive results for two anti-coagulant drugs

Regeneron (NASDAQ:REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to initiate Phase 3 testing next year.

The company said REGN7508 is designed to maximize anticoagulant activity while minimizing bleeding risk. REGN9933 is aimed at providing an option for patients with the highest bleeding risk who are not candidates for currently available anticoagulants.

The Phase 2 studies evaluated REGN7508 and REGN9933 in the prevention of asymptomatic or symptomatic venous thromboembolism, or VTE, after unilateral total knee arthroplasty.

Regeneron (NASDAQ:REGN) said a pooled analysis showed REGN7508 was superior to enoxaparin and non-inferior to apixaban, and REGN9933 was non-inferior to enoxaparin, according to a statement.

Pfizer (PFE) and Bristol-Myers Squibb (BMY) market apixaban under the brand name Eliquis, while Sanofi (SNY) sells enoxaparin under the name Lovenox. The drugs are also available generically.

Regeneron (REGN) added there was no major bleeding or clinically relevant non-major bleeding in any arm of the studies. Likewise, no treatment-related serious adverse events were reported.

The company plans to begin Phase 3 testing of the drugs in 2025.